Last reviewed · How we verify
NCT05739058
Violet-Blue Light Inactivation of Bacteria in Chronic Wounds
NA trial testing Violet-Blue Light Treatment / FlashHeal Device in Phototherapy Complication in 22 participants. Completed in 1 May 2024.
1 May 2024
Quick facts
| Lead sponsor | Bispebjerg Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 22 |
| Start date | 22 March 2023 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Violet-Blue Light Treatment / FlashHeal Device
Conditions studied
- Phototherapy Complication — all drugs for Phototherapy Complication →
- Photobiology — all drugs for Photobiology →
- Light Treatment; Complications — all drugs for Light Treatment; Complications →
- Wound Infection — all drugs for Wound Infection →
Sponsor
Bispebjerg Hospital
Who can join
18 and older, any sex, with Phototherapy Complication or Photobiology. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This four-week prospective clinical investigation will assess the safety and feasibility of a medical device without CE-marking. The medical device is a light-emitting-diode (LED) and is manufactured by VulCur MedTech Aps. Violet-blue light treatment is tested on a total of twenty-two patients with chronic wounds, divided into three groups, each group only receiving one dosage. Three dosages (low, medium and high) of violet-blue light treatment is tested. ID 1-7 are assigned to the low group, ID 8-15 are assigned to medium group and ID 16-22 are assigned to the high dosage group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05739058
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Bispebjerg Hospital trials
Trials by the same sponsor.
- NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
- NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
- NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
- NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
- NCT07096648 — Alert Burden When Monitoring Patients at Home · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05739058 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
- Last refreshed: 3 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05739058.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing